# Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)

> **NCT06963060** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Wei Gong** · enrollment: 44 (estimated)

## Conditions studied

- Gallbladder Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine nab-PaclitaxelLenvatinibTislelizumab

## Key facts

- **NCT ID:** NCT06963060
- **Lead sponsor:** Wei Gong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963060, "Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06963060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*